Rilpivirine Hydrochloride

盐酸利匹韦林

Report date: 2026/03/18 10:10:19
NME

Base Information

Drug NameRilpivirine Hydrochloride
Drug Alias Namerilpivirina利匹韦林盐酸盐利吡韦林rilpivirinum利匹韦林 +[19] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNon-nucleoside reverse transcriptase inhibitors
TargetsReverse transcriptase
Therapy Area/IndicationsContraception BehaviorHepatic InsufficiencyAcquired Immunodeficiency Syndrome +[4] 
Global Approved IndicationsHIV Infections
Approved Indications in ChinaHIV Infections
Original Approved Country/TerritoryUnited States
Original Approved Date2011/05/20
Country/TerritoryBelgiumCanadaBotswana +[34] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesJanssen Therapeutics, Division of Janssen Products, LP
China Registration ClassN/A

Develop Information

Active CompaniesJohnson & Johnson Innovative MedicineJanssen-Cilag International NvJanssen Products, Lp +[6] 
Inactive CompaniesJanssen Therapeutics, Division of Janssen Products, LPNational Institutes Of HealthTibotec Pharmaceuticals, Ireland +[7] 
Active IndicationsHIV Infections
Inactive IndicationsContraception BehaviorHepatic InsufficiencyAcquired Immunodeficiency Syndrome

Other Information

ATC CodeJ05AG05
Related LinksWikipediaDrugBankKEGG